Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors

RENO, Nev., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today announced that it has closed a private placement of approximately $5 million (the “Private Placement”); however, $250,000 of subscriptions, from certain members of management and the Board of Directors, are being held in escrow pending approval by the Company’s stockholders as required under Nasdaq Listing Rule 5635(c). Upon receipt of the required stockholder approval, the securities will be issued to the certain members of management and certain directors, and the $250,000 will be released to the Company. If stockholder approval is not obtained, the escrowed funds will be returned to the management and director subscribers, and the securities will not be issued to them. The Private Placement consists of 1,666,667 units (each, a “Unit”) at a price of $3.00 per Unit, with each Unit consisting of one share of common stock (a “Share”) and one warrant (a “Warrant”) to purchase one share of common stock at an exercise price of $3.00 per share, exercisable for 24 months from the date of issuance. For certain Canadian subscribers, the Company has issued special warrants (“Special Warrants”) instead of Units at $3.00 per Special Warrant, whereby each Special Warrant shall automatically be converted (without any further action or payment on the part of the holder) into one Share and one Warrant upon the earlier of (a) the date on which the final Canadian prospectus qualifying the distribution of the Units and underlying Shares and Warrants in British Columbia, Canada is receipted by the British Columbia Securities Commission, and (b) Feb. 16, 2027 (being the date that is four months and a day following Oct. 15, 2026).